Yale Cancer Center | Strategic Alliance Partners

Vincent T. DeVita, Jr, MD, Lymphoma: Giant of Cancer Care, Yale Cancer Center, discusses the use of chemotherapy for patients with Hodgkin's lymphoma.

Roy S. Herbst, MD, PhD, professor of Medicine at Yale Cancer Center and chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the differences of targeting PD-1 and PD-L1 when treating patients with lung cancer.

Roy S. Herbst, MD, PhD, chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses immunotherapy for patients with lung cancer.

Thomas J. Lynch, Jr., MD, from the Yale Cancer Center, pioneered the use of molecular testing for EGFR mutations in lung cancer. In July 2013, he was honored by OncLive as one of the "Giants of Cancer Care."

Ellen T. Matloff, MS, CGC, from the Yale School of Medicine/Yale Cancer Center, describes the impact of the US Supreme Court decision to restrict the patenting of segments of DNA in isolation.

The treatment of bone metastases in prostate cancer has changed over the years, and several options are now either available or under development.

Roy S. Herbst, MD, PhD, from the Yale Cancer Center, discusses determining the eligibility of patients with non-small cell lung cancer for molecular testing.

With increasing use of neoadjuvant chemotherapy in early-stage breast cancer, controversy has erupted regarding the optimal timing of sentinel lymph node biopsy.

While the number of known mutations and matching targeted agents is relatively limited at present, clinical trials are being designed to identify effective therapies for specific mutations more efficiently.

Scott Gettinger, MD, associate professor of medicine (medical oncology), Yale School of Medicine, explains the development of immunotherapies in lung cancer.

Patients who received sipuleucel-T developed immune parameters that correlated with improved overall survival suggesting that these parameters should be the focus of further studies on the treatment.

Dr. Roy S. Herbst, from Yale Cancer Center, Explores Molecular Testing in Lung Cancer

Roy S. Herbst, MD, PhD, is a physician and translational researcher, whose work in developing novel, personalized therapies for lung cancer has helped drive significant changes in the way the disease is treated.

Dr. Roy S. Herbst from Yale Comprehensive Cancer Center on Themes From the 2011 Lung Cancer Congress

Dr. Roy S. Herbst from Yale comprehensive cancer center on the International Lung Cancer Congress

Dr. Roy Herbst from the Yale Comprehensive Cancer Center on Screening Studies at the Upcoming Lung Cancer Congress